Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 526 to 550 of 2559

TitleReference numberPublishedLast updated
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessmentHTG663
Type 1 diabetes in adultsQS208
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Endoluminal gastroplication for gastro-oesophageal reflux diseaseHTG661
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionHTG662
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosisMIB317
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Urinary tract infections in adultsQS90
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopyMIB316
Antenatal careQS22
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Transvenous obliteration for gastric varicesHTG658
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863

Results per page

  1. 10
  2. 25
  3. 50
  4. All